Marksans Pharma Ltd share price logo

Marksans Pharma Share Price

NSE: MARKSANS

BSE: 524404

Small Cap

Healthcare Sector

₹168.15

+0.11

(+0.07%)

as on

bell
The current prices are delayed by 15 mins, login to check live prices.

Tech Chart

Marksans Pharma Stock Performance

as on April 2, 2026 at 9:31 pm IST

  • Day's Low

    Day's High

    ₹160.60
    ₹169.17
    downward going graph

    4.49%

    Downside

    0.61%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    ₹155.00
    ₹270.70
    downward going graph

    7.82%

    Downside

    60.99%

    Upside

    downward going graph

Marksans Pharma share price movements today

Previous Close
₹168.04
Open
₹163.66
Volume
5.51L
Upper Circuit
₹201.64
Lower Circuit
₹134.44
Day's Low - High
₹160.60 - ₹169.17
52 Week Low - High
₹155.00 - ₹270.70

Marksans Pharma Historical Returns

1 Month Return
-1.79 %
3 Month Return
-7.62 %
1 Year Return
-27.88 %
3 Year Return
+ 135.17 %
5 Year Return
+ 218.16 %

Marksans Pharma Fundamentals

as on April 2, 2026 at 4:01 pm IST

Market Cap

₹7,619.95 Cr

Return on Equity (ROE)

14.45

PE Ratio (TTM)

21.12

Return on capital employed (ROCE)

18.55

Industry PE ratio

40.5

Beta (LTM)

0

P/B Ratio

7.28

Dividend Yield

0.36

PEG Ratio

-124.26

Quarterly Earnings Growth YOY

8.2

EPS (TTM)

8.44

Sector

Pharmaceuticals

Book Value

54.44

Technical Analysis

Bearish

View Technical Analysis

Marksans Pharma Stock Valuation

as on April 2, 2026 at 4:01 pm IST

Marksans Pharma in the last 5 years

  • Overview

  • Trends

Lowest (4.67x)

April 1, 2020

Today (21.12x)

April 2, 2026

Industry (40.50x)

April 2, 2026

Highest (46.60x)

January 24, 2018

LowHigh

Today’s Price to Earnings Ratio: 21.12x

Marksans Pharma Ltd vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Marksans Pharma with its industry peers.

Company
Analyst View
Market Cap(in ₹ Cr)
5 Year CAGRDebt to Asset Ratio
Net Profit(in ₹ Cr)
Yearly Revenue(in ₹ Cr)
Marksans Pharma Ltd image
Marksans Pharma Ltd
BUY7,619.9543.63%0.563822,622
Zenith Health Care Ltd image
Zenith Health Care Ltd
NA16.07-9.45%0.00NA11
Acutaas Chemicals Ltd image
Acutaas Chemicals Ltd
BUY17,276.4470.28%0.511601,006
FDC Ltd image
FDC Ltd
NA5,425.653.44%0.512662,108
Vasundhara Rasayans Ltd image
Vasundhara Rasayans Ltd
NA35.4410.74%0.00433
See all

Market expectation of Marksans Pharma Stock

Common consensus of the market based on various publicly available news, publications,brokerage expectation and market data

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Marksans Pharma Stock’s Investor Sentiment and Interest

Investment in Marksans Pharma Ltd Shares on INDmoney has dropped by -12.24% over the past 30 days, indicating reduced transactional activity.

Time period: to

Change:-12.24% versus previous 30 day period

Search interest for Marksans Pharma Ltd Stock has decreased by -40% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-40% versus previous 30 day period

Marksans Pharma Ltd Quarterly Profit & Loss

Figures in Rupees Crores

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Sales
500.03
531.24
586.13
560.01
590.62
641.92
681.85
708.46
619.99
720.41
754.43
Other Income
10.1
19
4.8
16.53
14.95
-0.07
27.85
15.34
5.64
21.57
20.14
Total Income
510.13
550.23
590.93
576.54
605.57
641.85
709.7
723.8
625.63
741.98
774.57
Expenses
398.07
417.29
453.11
450.37
462.18
495.11
543.08
581.52
519.87
575.92
593.69
Operating Profit
101.96
113.95
133.02
109.64
128.44
146.81
138.77
126.94
100.12
144.49
160.74
Operating Profit Margin %
20.39%
21.45%
22.69%
19.58%
21.75%
22.87%
20.35%
17.92%
16.15%
20.06%
21.31%
Profit Before Interest, Tax and Depreciation
112.06
132.95
137.82
126.17
143.39
146.74
166.61
142.27
105.76
166.07
180.89
Interest
1.58
1.63
3.16
4.84
2.92
2.63
2.67
3.44
6.07
5.82
5.94
Depreciation
13.66
17.55
22
21.06
20.44
19.51
20.69
22.74
23.1
26.92
24.33
Profit Before Tax
96.82
113.77
112.66
100.27
120.03
124.6
143.25
116.09
76.59
133.33
150.62
Tax Paid
26.38
29.91
29.7
22.63
30.95
26.84
38.19
25.37
18.4
34.2
36.94
Profit After Tax
70.44
83.85
82.97
77.64
89.07
97.76
105.07
90.73
58.2
99.14
113.69
Total Net profit including share of profit / Loss from associate company
70.44
83.85
82.97
77.64
89.07
97.76
105.07
90.73
58.2
99.14
113.69
EPS
1.52
1.84
1.84
1.73
1.96
2.13
2.31
2
1.29
2.17
2.5
Actual EPS
1.52
1.84
1.84
1.73
1.96
2.13
2.31
2
1.29
2.17
2.5
Adjusted EPS
1.52
1.84
1.84
1.73
1.96
2.13
2.31
2
1.29
2.17
2.5
Diluted EPS
1.52
1.84
1.84
1.73
1.96
2.13
2.31
2
1.29
2.17
2.5

Marksans Pharma Ltd Annual Profit & Loss

Figures in Rupees Crores

Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Sales
912.69
1,000.07
1,134.21
1,376.18
1,490.84
1,852.14
2,177.41
2,622.85
Other Income
8.47
4.62
0.33
6.69
41.85
59.31
50.42
66.33
Total Income
921.17
1,004.69
1,134.54
1,382.88
1,532.69
1,911.45
2,227.83
2,689.17
Expenses
834.31
867.92
941.96
1,036.58
1,231.96
1,512.82
1,718.83
2,090.16
Operating Profit
78.38
132.15
192.25
339.6
258.88
339.32
458.58
532.69
Operating Profit Margin %
8.59%
13.21%
16.95%
24.68%
17.36%
18.32%
21.06%
20.31%
Profit Before Interest, Tax and Depreciation
86.86
136.77
192.58
346.3
300.73
398.63
509
599.01
Interest
10.22
9.66
8.75
7.99
8.45
9.13
11.2
11.66
Depreciation
26.84
22.8
26.66
36.15
44.78
51.85
74.27
83.39
Profit Before Tax
49.8
104.31
157.17
302.16
247.5
337.65
423.53
503.96
Tax Paid
14
23.88
36.42
63.62
60.7
72.33
108.63
121.35
Profit After Tax
35.8
80.44
120.75
238.54
186.81
265.32
314.9
382.62
Total Net profit including share of profit / Loss from associate company
35.8
80.44
120.75
238.54
186.81
265.32
314.9
382.62
EPS
0.8
1.87
2.86
5.76
4.51
6.41
6.92
8.4
Actual EPS
0.8
1.87
2.86
5.76
4.51
6.41
6.92
8.4
Adjusted EPS
0.8
1.87
2.86
5.76
4.51
6.41
6.92
8.4
Diluted EPS
0.8
1.87
2.86
5.76
4.51
6.41
6.92
8.4

Marksans Pharma Ltd Cash Flow

Figures in Rupees Crores

Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Net Cash from Operating Activities
30.8
14.06
50.09
27.4
233.33
178.59
99.26
237.41
230.41
206.66
Cash Flow from Investing Activities
-123.01
-20.72
-38.81
-13.48
-59.59
-44.85
-84.4
-259.2
-140.84
-49
Cash Flow from Financing Activities
-57.75
-3.48
3.39
-20.78
-113.56
-15.28
79.52
197.83
-68.73
-65.16
Net Cash Flow
-149.96
-10.14
14.67
-6.86
60.19
118.46
94.38
176.03
20.84
92.51

Marksans Pharma Stock Shareholding Pattern

Numbers in percentages

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Promoters
43.85%
43.85%
43.85%
43.85%
43.87%
43.87%
43.87%
43.87%
43.87%
43.87%
43.87%
DII
3.65%
3.15%
3.82%
5.17%
3.75%
4.1%
4.3%
4.56%
5.5%
5.28%
5.91%
FII
10.88%
10.88%
10.88%
15.57%
18.6%
21.31%
21.96%
22.2%
19.88%
16.92%
8.12%
Public
37.59%
37.06%
35.83%
35.4%
33.78%
30.71%
29.87%
29.37%
30.75%
33.93%
42.09%
Total Outstanding Shares
45,31,63,746
45,31,63,746
45,31,63,746
45,31,63,746
45,31,63,746
45,31,63,746
45,31,63,746
45,31,63,746
45,31,63,746
45,31,63,746
45,31,63,746
Total Shareholders
1,88,447
2,07,937
2,37,377
2,54,699
2,35,500
2,48,845
2,59,813
2,57,273
2,56,221
2,65,788
2,55,153

Mutual Funds that own Marksans Pharma Stock

Check out the Mutual Funds with significant holdings in Marksans Pharma.

Marksans Pharma Corporate Actions

View detailed summary of the earnings and dividend history of Marksans Pharma.

  • Marksans Pharma Ltd Earnings Results

    Marksans Pharma Ltd’s net profit jumped 8.26% since last year same period to ₹113.20Cr in the Q3 2025-2026. On a quarterly growth basis, Marksans Pharma Ltd has generated 15.22% jump in its net profits since last 3-months.

    Read More about Earnings Results

  • Marksans Pharma Ltd Dividends May,2025

    In the quarter ending March 2025, Marksans Pharma Ltd has declared dividend of ₹0.80 per share on 19 May 2025 - translating a dividend yield of 0.83%.

    Read More about Dividends

Indices Featuring Marksans Pharma Stock

Check stock indices that include Marksans Pharma.

BSE Healthcare

₹41,371.63

-0.75 (▲312.71%)

Insights on Marksans Pharma Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 3.92% to 4.41% in Dec 2025 quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 6 months, MARKSANS stock has moved up by 1.0%

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, 58.32 Cr → 113.2 Cr (in ₹), with an average increase of 26.9% per quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 625.63 Cr → 774.57 Cr (in ₹), with an average increase of 9.9% per quarter

  • imgPOSITIVE IMPACT

    Retail Holding Up

    img

    Retail Investor have increased holdings from 33.93% to 42.09% in Dec 2025 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Torrent Pharmaceuticals Ltd has given 22.8% return, outperforming this stock by 50.7%

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 43.87% of holdings in Dec 2025 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Lupin Ltd has given 249.0% return, outperforming this stock by 113.8%

  • imgNEGATIVE IMPACT

    FII Holding Down

    img

    Foreign Institutions have decreased holdings from 8.30% to 8.12% in Dec 2025 quarter

About Marksans Pharma Ltd

Marksans Pharma Limited is a public limited company that specializes in research, manufacture, marketing and sale of pharmaceutical formulations. Established in April 1982, the Company has its research and development centers located in Verna Goa and Navi Mumbai. On 30th March 2015, they issued and allotted 24006494 equity shares of ₹1 each to qualified institutional buyers for ₹54.67 per share under QIP. On 7th February 2015, the Company decided to redeem 1350000 cumulative redeemable preference shares of face value ₹100 each out of profits in tranches before due date of redemption, which was decided to be 27th March 2018. 50000 Bonds of USD 1000 value each were issued during the financial year 2015, out of which 49939 Bonds were bought and extinguished by the Company. 150000 preference shares of ₹100 each were redeemed at par in 2017 and the issued, subscribed and paidup preference share capital was reduced to 1100000 of ₹100 each. Marksans Pharma Limited is a long-standing public limited company offering research, manufacture, marketing and sale of pharmaceutical formulations.

Revenue: ₹754.43Cr as on December 2025 (Q3 FY26)
Net Profit: ₹113.69Cr as on December 2025 (Q3 FY26)
Listing date: 21 Jan, 2002
Chairperson Name: Mark Saldanha
OrganisationMarksans Pharma Ltd
HeadquartersMumbai
IndustryPharmaceuticals
CEOMark Saldanha
E-voting on sharesClick here to vote

FAQs

What is Marksans Pharma share price today?

Marksans Pharma share price today stands at ₹168.15 as on at the close of the market. Marksans Pharma share today touched a day high of ₹169.17 and a low of ₹160.6.

What is the 52 week high and 52 week low range for Marksans Pharma share?

Marksans Pharma touched a 52 week high of ₹270.7 and a 52 week low of ₹155. Marksans Pharma share price today i.e. is closed at ₹168.15, which is -37.88% down from its 52 week high and 8.48% up from its 52 week low.

What is Marksans Pharma's market capitalisation today?

Marksans Pharma market capitalisation is ₹7,619.95 Cr as on .

How to buy Marksans Pharma shares?

To buy Marksans Pharma shares, you need to follow these steps:

  • Open a Demat account and Trading account on INDmoney
  • Fund your Trading account
  • Search for MARKSANS or Marksans Pharma Ltd on the INDmoney app to check live prices of the stock
  • Click on Buy or SIP to place an order to invest in Marksans Pharma shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.

What is Marksans Pharma trading volume today?

Marksans Pharma trading volume is 5.51L as on . This means that 5.51L shares of Marksans Pharma were bought and sold on the stock market during today's trading session.